Quantcast

Latest Gene therapy Stories

2014-03-19 23:00:54

ReportsnReports.com adds “Cancer Gene Therapy Market Analysis” report to its research database. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Dallas, TX (PRWEB) March 20, 2014 The gene therapy market has undergone a series of transformation from the initial days of research to the current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the...

2014-03-11 04:21:27

BARCELONA, Spain, March 11, 2014 /PRNewswire/ -- - This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fatima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autonoma de Barcelona (UAB) - ESTEVE announce the signing of agreements with REGENX and GENETHON which will allow it to initiate its phase I/II clinical trial in 2015 -...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...

2014-03-05 16:26:40

Treatment with Sangamo's ZFN- Modified T-cells (SB-728-T) Provides Functional Control of HIV without Antiretroviral Drugs RICHMOND, Calif., March 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Data from the study, carried out in HIV-positive subjects, demonstrate that the T-cell...

Gene Therapy Could Possibly Grow Replacement Cartilage Inside The Body
2014-02-19 14:47:12

Ken Kingery - Duke University Pratt School of Engineering Duke researchers use gene therapy to direct stem cells into becoming new cartilage on a synthetic scaffold even after implantation into a living body By combining a synthetic scaffolding material with gene delivery techniques, researchers at Duke University are getting closer to being able to generate replacement cartilage where it's needed in the body. Performing tissue repair with stem cells typically requires applying...

2014-02-11 08:32:36

Company continues to expand its board and leadership team as it moves toward completion of its Phase 3 gene therapy program and advancement of the industry's deepest pipeline of gene-based medicines PHILADELPHIA, Feb. 11, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today the appointment of Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of...

2014-02-10 20:21:08

Call on FDA for Accelerated Approval of Promising Duchenne Muscular Dystrophy Treatment WASHINGTON, Feb. 10, 2014 /PRNewswire-iReach/ -- Health staffers from over 80 Congressional offices together with agency and industry officials jammed a briefing room last Friday to hear mothers, clinicians and leading researchers call on the FDA to accept and promptly review a new drug application for eteplirsen, a promising new treatment for Duchenne Muscular Dystrophy that could save thousands...

2014-02-04 12:28:02

CINCINNATI, Feb. 4, 2014 /PRNewswire-USNewswire/ -- Researchers used blood platelets and bone marrow cells to deliver potentially curative gene therapy to mouse models of the human genetic disorder Hurler syndrome - an often fatal condition that causes organ damage and other medical complications. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Scientists from Cincinnati Children's Hospital Medical Center and the National Institute of Neurological Disorders and...

2014-02-04 08:36:15

CLEVELAND, Feb. 4, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for the treatment of cardiovascular disease, announced today that it has initiated enrollment of the Phase II RETRO-HF clinical trial to evaluate safety and efficacy of JVS-100 delivered via retrograde infusion to patients with symptomatic heart failure. Co-principal investigators for the trial are Drs. Amit Patel, M.D., Director...

Precise Gene Modification In Monkeys Paves Way For Valuable Human Disease Models
2014-01-30 15:58:45

Cell Press Monkeys are important for modeling diseases because of their close similarities to humans, but past efforts to precisely modify genes in primates have failed. In a study published by Cell Press January 30th in the journal Cell, researchers achieved precise gene modification in monkeys for the first time using an efficient and reliable approach known as the CRISPR/Cas9 system. The study opens promising new avenues for the development of more effective treatments for a range of...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.